Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 4

NAVIDEA I Form 4 July 06, 201	BIOPHARMACEUTI(5	CALS, INC.				
FORM			OMB APPROVAL			
	UNITED STA	Washington, D.C. 20549				
Check th if no long subject to Section 1	ser STATEMEN	T OF CHANGES IN BENEFICIAL OW SECURITIES	NERSHIP OF NERSHIP OF Estimated average burden hours per response 0.5			
Form 4 c Form 5 obligatio may cont <i>See</i> Instr 1(b).	Filed pursuant sinue. Section 17(a) of	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, ection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940				
(Print or Type I	Responses)					
1. Name and A GUETH AN	Address of Reporting Persor	Symbol	5. Relationship of Reporting Person(s) to Issuer			
		NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]	(Check all applicable) X_ Director 10% Owner			
(Last) 5600 BLAZ 200	(First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year) TE 07/02/2015	Officer (give titleOther (specify below) below)			
	(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
DUBLIN, C	OH US 43017		Form filed by More than One Reporting Person			
(City)	(State) (Zip)	Table I - Non-Derivative Securities Act	uired, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)	any	Deemed 3. 4. Securities Acquired ution Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) nth/Day/Year) (Instr. 8) (A) or	5. Amount of Securities6.7. Nature of IndirectBeneficiallyForm: DirectBeneficialOwned(D) orOwnershipFollowingIndirect (I)(Instr. 4)Reported(Instr. 4)Transaction(s)(Instr. 3 and 4)			
Common Stock	07/02/2015	Code V Amount (D) Price A 22,000 A $\begin{pmatrix} \$ \\ 0.001 \end{pmatrix}$	22 000 D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. ionNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	5	Date	Amou Under Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	•	Other	
GUETH ANTON 5600 BLAZER PARKWAY SUITE 200 DUBLIN, OH US 43017	Х				
Signatures					
William J. Kelly, attorney-in-fact	0′	7/06/2015			
**Signature of Reporting Person		Date			

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.